The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis.

ABSTRACT:

Background

The presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies in dermatomyositis (DM) is associated with an increased risk of developing rapidly progressive interstitial lung disease (RP-ILD) and a poor prognosis.

Objectives

We aimed to explore whether tofacitinib could improve the prognosis of Anti-MDA5 antibody positive DM-interstitial lung disease (ILD).

Design

Systematic review and meta-analysis.

Data sources and methods

Studies were included if they compared mortality rate and infection events in patients with anti-MDA5 antibody positive DM-associated ILD who were treated with or without tofacitinib.

Results

The systematic review and meta-analysis included a total of 148 patients from four cohort studies. Fifty-eight p

SUBMITTER: Wang Y 

PROVIDER: S-EPMC11528585 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature